NERV

Minerva Neurosciences Inc

2.20

Oct 26 • 3:59 PM ET -0.10 (-4.35%)

2.20

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: MPLT LBRX NMRA ANRO ACAD VNDA AVXL AXSM ALKS SUPN

| Held by: VTI IWM VXF VTWO IWO IWC IWN VTWG QQQS RSSL

Scroll to Statements

Index	RUT
Market Cap	105.05M
Enterprise Value	101.42M
Income	-395.17M
Sales	0.00M
Book/sh	-4.52
Cash/sh	1.58
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Jul 01, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	1.39
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	20.14
Current Ratio	20.14
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-28.87
EPS next Y	-0.68
EPS next Q	-0.17
EPS this Y	-33.33%
EPS next Y	73.02%
EPS next 5Y	36.24%
EPS past 3/5Y	-79.32% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-2012.66%
Sales Y/Y TTM	-
EPS Q/Q	67.97%
Sales Q/Q	-
Earnings	Aug 07 BMO
EPS/Sales Surpr.	27.57% -

Insider Own	21.08%
Insider Trans	0.00%
Inst Own	75.27%
Inst Trans	6.53%
ROA	-628.40%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-21.84%
SMA50	-40.22%
SMA200	-55.47%
Trades

Shs Outstand	47.23M
Shs Float	37.68M
Short Float	6.46%
Short Ratio	13.66
Short Interest	2.44M
52W High	8.80 -75.00%
52W Low	2.24 -1.79%
Volatility	10.71% 8.91%
ATR (14)	0.26
RSI (14)	25.69
Beta	0.05
Rel Volume	0.97
Avg Volume	178.26K
Volume	172,853

Perf Week	-5.17%
Perf Month	-35.29%
Perf Quarter	-48.60%
Perf Half Y	-65.79%
Perf YTD	-45.27%
Perf Year	-53.19%
Perf 3Y	-51.22%
Perf 5Y	-79.93%
Perf 10Y	-97.56%
Recom	1.67
Target Price	10.33
Prev Close	2.30
Price	2.20
Change %	-4.35%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-26	Upgrade	Jefferies	Hold → Buy	$10
Apr-15-26	Initiated	Citizens	Mkt Outperform	$14
Jun-08-20	Reiterated	H.C. Wainwright	Buy	$20 → $10
May-14-20	Initiated	BTIG Research	Buy	$23
Oct-02-19	Reiterated	Chardan Capital Markets	Buy	$17
Sep-25-19	Initiated	Chardan Capital Markets	Buy	$17
Sep-18-19	Initiated	William Blair	Outperform
May-31-19	Initiated	H.C. Wainwright	Buy
Sep-01-17	Initiated	Citigroup	Buy	$11
Mar-06-17	Resumed	Jefferies	Buy	$17
May-12-16	Resumed	Jefferies	Buy

Show Previous Ratings

Aug-28-26 08:00AM	Minerva Neurosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -5.65%
Aug-07-26 07:20AM	Minerva Neurosciences: Q2 Earnings Snapshot (Associated Press)
07:00AM	Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Jun-01-26 04:05PM	Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs (GlobeNewswire)
May-18-26 04:05PM	Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) -9.02% -8.02%
08:07AM	Loading…
May-05-26 08:07AM	Minerva Neurosciences: Q1 Earnings Snapshot (Associated Press)
08:00AM	Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Apr-02-26 04:05PM	Minerva Announces Leadership Transition (GlobeNewswire) -5.71%
Mar-31-26 04:05PM	Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia (GlobeNewswire) -7.05%
Mar-25-26 04:05PM	Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 (GlobeNewswire)
Mar-12-26 07:00AM	Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum (GlobeNewswire) +5.34%
Mar-11-26 07:20AM	Minerva Neurosciences: Q4 Earnings Snapshot (Associated Press Finance) -8.06%
07:00AM	Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates (GlobeNewswire)
Mar-04-26 07:00AM	Minerva Neurosciences to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Feb-04-26 02:07AM	Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia (MarketBeat) -5.27%
07:00AM	Loading…
Jan-26-26 07:00AM	Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 (GlobeNewswire)
Nov-19-25 08:30AM	Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors (GlobeNewswire)
Nov-05-25 07:40AM	Minerva Neurosciences: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Oct-21-25 08:00AM	Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved (GlobeNewswire) +140.98%
Aug-14-25 04:43PM	Minerva Neurosciences: Q2 Earnings Snapshot (Associated Press Finance) +25.35%
04:35PM	Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results (GlobeNewswire)
May-13-25 07:30AM	Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
07:22AM	Minerva Neurosciences: Q1 Earnings Snapshot (Associated Press Finance)
Feb-25-25 07:32AM	Minerva Neurosciences: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-05-24 07:40AM	Minerva Neurosciences: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-06-24 01:53PM	NERV Stock Earnings: Minerva Neurosciences Misses EPS for Q2 2024 (InvestorPlace) +5.00%
07:34AM	Minerva Neurosciences: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
May-06-24 12:00PM	Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-01-24 01:53PM	NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024 (InvestorPlace)
07:43AM	Minerva Neurosciences: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Feb-27-24 08:11AM	US FDA declines to approve Minerva Neurosciences' schizophrenia drug (Reuters) -58.82%
08:00AM	Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia (GlobeNewswire)
06:31AM	Minerva schizophrenia drug rejected by FDA (BioPharma Dive)
Feb-22-24 07:41AM	Minerva Neurosciences: Q4 Earnings Snapshot (Associated Press Finance) -17.61%
07:00AM	Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates (GlobeNewswire)
Nov-07-23 07:47AM	Minerva Neurosciences: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates (GlobeNewswire)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-01-23 07:40AM	Minerva Neurosciences: Q2 Earnings Snapshot (Associated Press Finance) +9.15%
07:30AM	Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates (GlobeNewswire)
Jun-28-23 08:30AM	Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market (GlobeNewswire) +69.27%
Jun-09-23 09:55AM	Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-18-23 12:00PM	What Makes Minerva Neurosciences (NERV) a New Buy Stock (Zacks) +10.15%
May-15-23 09:57PM	Q1 2023 Minerva Neurosciences Inc Earnings Call (Thomson Reuters StreetEvents) -11.42% -12.42%
07:40AM	Minerva Neurosciences: Q1 Earnings Snapshot (AP Finance)
07:30AM	Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates (GlobeNewswire)
May-10-23 08:00AM	Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire) +13.68%
May-08-23 08:30AM	Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023 (GlobeNewswire)
May-01-23 07:00AM	Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire) +34.29%
Mar-10-23 02:24AM	Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.01%
Mar-08-23 11:12PM	Q4 2022 Minerva Neurosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.65%
07:30AM	Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates (GlobeNewswire)
Mar-01-23 08:30AM	Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 (GlobeNewswire)
Dec-29-22 10:18AM	Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA (Zacks) +5.59%
05:30AM	The Petri Dish: Group eyes Biogen Alzheimer's drug price, FDA rejects psych drug application (American City Business Journals)
Dec-28-22 08:00AM	Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire) -39.15%
Nov-09-22 08:00AM	Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +8.85%
Nov-02-22 08:30AM	Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022 (GlobeNewswire) +6.52%
Oct-20-22 11:28AM	Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More (Zacks)
Oct-17-22 09:18AM	Minerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia Candidate (Benzinga) -69.55%
08:51AM	Minerva Neurosciencs to request meeting with FDA about schizophrenia drug (MarketWatch)
08:30AM	Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire)
Sep-26-22 09:21AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Sep-09-22 04:05PM	Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Aug-31-22 06:25PM	The 5 Bestand 5 WorstNasdaq Stocks in August (Barrons.com) -14.35% -14.18%
Aug-23-22 12:38PM	Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up (Zacks)
Aug-22-22 08:00AM	Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia (GlobeNewswire) +47.83%
Aug-12-22 09:55AM	Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher (Zacks)
Aug-09-22 08:00AM	Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -23.89%
Jun-22-22 08:58AM	Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation (Simply Wall St.) -5.26%
May-04-22 08:30AM	Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
Apr-07-22 09:57AM	Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study (Zacks)
08:30AM	Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire)
Mar-21-22 09:52AM	Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder (Zacks)
Mar-01-22 09:05AM	Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Feb-28-22 08:30AM	Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin (GlobeNewswire)
Dec-01-21 07:44AM	Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth? (Simply Wall St.) -6.82%
Nov-08-21 08:45AM	Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Nov-03-21 08:30AM	Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission (GlobeNewswire)
Nov-01-21 08:30AM	Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 (GlobeNewswire)
Oct-11-21 08:30AM	Minerva Neurosciences Announces Promotion of Geoff Race to President (GlobeNewswire)
Oct-01-21 07:00AM	15 Stocks Moving in Friday's Pre-Market Session (Benzinga) -9.20%
Sep-30-21 10:32AM	Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations (Benzinga)
08:30AM	Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia (GlobeNewswire)
Sep-27-21 08:30AM	Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options (Zacks)
Sep-08-21 08:30AM	Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development (GlobeNewswire)
Aug-02-21 08:55AM	Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Jul-26-21 03:01PM	Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:30AM	Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 (GlobeNewswire)
Jun-10-21 08:30AM	Minerva Neurosciences to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-04-21 05:20AM	What Type Of Shareholders Own The Most Number of Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares? (Simply Wall St.)
May-28-21 08:00AM	Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Federated Hermes Kaufmann Fund	10% Owner	Mar 31 '26	Proposed Sale	8.00	8,798	70,384	Mar 31 05:00 PM
Federated Hermes Kaufmann Smal	10% Owner	Mar 31 '26	Proposed Sale	8.00	19,838	158,704	Mar 31 04:57 PM
Federated Hermes Kaufmann Fund	10% Owner	Mar 31 '26	Proposed Sale	8.00	31,808	254,464	Mar 31 04:57 PM
Federated Hermes Kaufmann Fund	10% Owner	Mar 10 '26	Proposed Sale	8.00	12,456	99,648	Mar 10 05:20 PM
Federated Hermes Kaufmann Smal	10% Owner	Mar 10 '26	Proposed Sale	8.00	264,615	2,116,920	Mar 10 05:15 PM
Federated Hermes Kaufmann Fund	10% Owner	Mar 10 '26	Proposed Sale	8.00	424,278	3,394,224	Mar 10 05:15 PM

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Executive ChairmanDr. Remy Luthringer Ph.D.

Senior VPMr. Frederick W. Ahlholm CPA

Senior VP & COOMr. Joseph Reilly

Chief Accounting Officer & Principal Accounting OfficerMr. Anthony Aliquo

Vice President of Investor Relations & Corporate CommunicationsMr. William B. Boni

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NERV

Minerva Neurosciences Inc

Upgrade your Finviz experience